Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhengyang Yang

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Advanced Materials (Deerfield Beach, Fla.)|February 5, 2026
STAR Therapy: Spatiotemporal Antitumor Regimen via a Size-Gated DNA Hydrogel Drug Delivery SystemChengyu Feng, Zhengyang Yang, Yufei Lan, et al.
Signal Transduction and Targeted Therapy|March 11, 2024
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 studyZhengyang Yang, Jiale Gao, Jianyong Zheng, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 28, 2026
Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trialZhengyang Yang, Zhuan Xu, Liting Sun, et al.
Frontiers in Oncology|February 23, 2023
Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancerJiale Gao, Xiao Zhang, Zhengyang Yang, et al.
BMC Cancer|April 28, 2022
Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)Zhengyang Yang, Xiao Zhang, Jie Zhang, et al.
Med (New York, N.Y.)|July 24, 2024
Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancerZhengyang Yang, Jingxin Ma, Jiagang Han, et al.
Gut|February 26, 2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancerZhengyang Yang, Fan Xia, Jian Li, et al.
Extracellular Vesicles and Circulating Nucleic Acids|February 16, 2026
80 years of extracellular vesicles: from discovery to clinical translationQiang Li, Yinan Ding, Yejiao Shi, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Advanced Materials (Deerfield Beach, Fla.)|February 5, 2026
STAR Therapy: Spatiotemporal Antitumor Regimen via a Size-Gated DNA Hydrogel Drug Delivery SystemChengyu Feng, Zhengyang Yang, Yufei Lan, et al.
Signal Transduction and Targeted Therapy|March 11, 2024
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 studyZhengyang Yang, Jiale Gao, Jianyong Zheng, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 28, 2026
Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trialZhengyang Yang, Zhuan Xu, Liting Sun, et al.
Frontiers in Oncology|February 23, 2023
Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancerJiale Gao, Xiao Zhang, Zhengyang Yang, et al.
BMC Cancer|April 28, 2022
Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)Zhengyang Yang, Xiao Zhang, Jie Zhang, et al.
Med (New York, N.Y.)|July 24, 2024
Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancerZhengyang Yang, Jingxin Ma, Jiagang Han, et al.
Gut|February 26, 2026
Consensus guidance of immune checkpoint inhibitors in locally advanced rectal cancerZhengyang Yang, Fan Xia, Jian Li, et al.
Extracellular Vesicles and Circulating Nucleic Acids|February 16, 2026
80 years of extracellular vesicles: from discovery to clinical translationQiang Li, Yinan Ding, Yejiao Shi, et al.
Pageof 5